M&T Bank Corp Buys Shares of 48,152 Qiagen N.V. $QGEN

M&T Bank Corp purchased a new position in shares of Qiagen N.V. (NYSE:QGEN) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 48,152 shares of the company’s stock, valued at approximately $2,186,000.

Several other hedge funds have also modified their holdings of QGEN. United Services Automobile Association purchased a new stake in Qiagen during the first quarter worth approximately $239,000. Prudential Financial Inc. increased its stake in shares of Qiagen by 74.9% in the second quarter. Prudential Financial Inc. now owns 8,873 shares of the company’s stock worth $426,000 after buying an additional 3,799 shares during the last quarter. Invesco Ltd. raised its stake in shares of Qiagen by 123.7% in the 2nd quarter. Invesco Ltd. now owns 1,006,025 shares of the company’s stock valued at $48,350,000 after purchasing an additional 556,387 shares in the last quarter. EverSource Wealth Advisors LLC grew its position in shares of Qiagen by 226.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,598 shares of the company’s stock worth $125,000 after acquiring an additional 1,802 shares in the last quarter. Finally, First Trust Advisors LP acquired a new position in Qiagen in the second quarter worth $3,639,000. 70.00% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on QGEN shares. Citigroup lowered their price objective on Qiagen from $55.00 to $38.00 and set a “neutral” rating for the company in a research note on Wednesday, April 29th. Stifel Nicolaus set a $50.00 target price on Qiagen and gave the stock a “hold” rating in a report on Friday, February 6th. Weiss Ratings reissued a “hold (c)” rating on shares of Qiagen in a report on Friday, March 27th. Wall Street Zen lowered Qiagen from a “buy” rating to a “hold” rating in a research note on Saturday, March 28th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $43.00 price target on shares of Qiagen in a research report on Thursday, April 30th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $46.38.

Qiagen Stock Down 1.4%

Shares of QGEN opened at $33.05 on Friday. The firm has a market capitalization of $6.81 billion, a P/E ratio of 17.26, a P/E/G ratio of 3.34 and a beta of 0.64. Qiagen N.V. has a 52 week low of $32.92 and a 52 week high of $57.81. The company has a 50-day simple moving average of $40.93 and a 200-day simple moving average of $46.38. The company has a debt-to-equity ratio of 0.44, a quick ratio of 3.31 and a current ratio of 3.90.

Qiagen (NYSE:QGEN) last issued its earnings results on Wednesday, May 6th. The company reported $0.54 EPS for the quarter, meeting the consensus estimate of $0.54. Qiagen had a net margin of 19.16% and a return on equity of 14.09%. The company had revenue of $492.32 million for the quarter, compared to the consensus estimate of $496.15 million. During the same quarter in the previous year, the company earned $0.56 EPS. On average, equities research analysts expect that Qiagen N.V. will post 2.43 earnings per share for the current year.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library?preparation kits and proteomics solutions.